As the Nasdaq reaches record highs driven by surges in chip stocks and Apple, while the S&P 500 shows signs of losing momentum, investors are keenly observing market fluctuations influenced by tariff ...

Get insights from Ligand Pharmaceuticals' Q2 2025 earnings—57% royalty revenue growth, raised guidance, and key partnerships driving long-term growth.

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Palleon Pharmaceuticals has dosed the first subject in the randomised Phase II trial of E-602 (HLX79), a first-in-class human ...

Research indicates that high-dose vitamin D improves bone health in very low birth weight preterm infants, highlighting its ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...

The company said it plans to develop its new Chai‑2 platform to design, from square one, completely new antibodies for ...

EyePoint Pharmaceuticals completed enrollment in the LUCIA trial, its second phase 3 trial of Duravyu in patients with wet ...

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

Inhibiting S100A9 or blocking TLR4/RAGE receptors impairs ETV5-mediated recruitment of suppressive myeloid cells in HCC.

Researchers developed a high-accuracy method to infer whether genetic variants come from the mother or father without needing ...

Treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy are under review.